Deutsche Bank set a €87.00 ($97.75) target price on Bayer (FRA:BAYN) in a research report report published on Wednesday morning, Borsen Zeitung reports. The brokerage currently has a buy rating on the healthcare company’s stock.

Several other research firms have also commented on BAYN. DZ Bank reissued a buy rating on shares of Bayer in a report on Tuesday, July 7th. Goldman Sachs Group set a €74.00 ($83.15) price target on shares of Bayer and gave the company a buy rating in a research note on Monday, July 27th. Morgan Stanley set a €88.00 ($98.88) target price on shares of Bayer and gave the stock a buy rating in a research note on Thursday, June 25th. UBS Group set a €110.00 ($123.60) price objective on shares of Bayer and gave the stock a buy rating in a research report on Wednesday, July 22nd. Finally, JPMorgan Chase & Co. set a €77.00 ($86.52) price target on shares of Bayer and gave the company a neutral rating in a research note on Wednesday, July 22nd. Five analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Bayer has a consensus rating of Buy and an average price target of €85.31 ($95.86).

Shares of BAYN stock opened at €56.24 ($63.19) on Wednesday. The company has a fifty day moving average price of €65.21 and a two-hundred day moving average price of €64.03. Bayer has a one year low of €91.58 ($102.90) and a one year high of €123.82 ($139.12).

Bayer Company Profile

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Further Reading: How to find the components of the quick ratio

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.